Studies have shown that SGLT2 inhibitors could have CV protective functions, probably by reducing endothelial oxidative stress (OS) via inhibition of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation (15, 16), decreasing cardiac preload and afterload via diuretic and natriuretic actions (6), alleviating sodium and calcium overload in cardiomyocytes by inhibiting sodium/hydrogen exchanger-1 (NHE-1) (17), reducing myocardial fibrosis (18), and modulating adipokines and inflammatory mediators (19–21). The gene discussed is SLC9A1; the disease is Myocardial fibrosis.